Covance links with Inserm on R&D

USA-based  contract research organization Covance (NYSE: CVD) has signed a four-year scientific collaboration agreement for R&D with the French National Institute of Health and Medical Research (Inserm) subsidiary Inserm Transfert SA, and seed investment company Inserm Transfert Initiative.

Under terms of the accord, Covance will conduct discovery and early development studies, using its global capabilities including those at its facilities in Porcheville, France, and Alnwick, UK, for projects managed by Inserm Transfert, the knowledge transfer company of Inserm, and preclinical studies for start-ups within Inserm Transfert Initiative's portfolio. These Inserm Transfert Initiative companies will also gain access to the extensive scientific, operational and program management expertise Covance provides across all areas of drug discovery and development.

Milestone in European relationships